AI Tokens
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

Pfizer Inc., liquidity ratios (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Current ratio 1.42 1.27 1.25 1.16 1.28 1.16 1.26 1.17 1.00 0.86 1.05 0.91 2.38 2.12 1.37 1.22 1.59 1.42 1.39
Quick ratio 0.90 0.74 0.75 0.69 0.80 0.67 0.80 0.74 0.56 0.42 0.57 0.50 1.78 1.59 0.88 0.80 1.18 1.02 0.95
Cash ratio 0.45 0.36 0.38 0.37 0.41 0.35 0.48 0.48 0.23 0.16 0.29 0.27 1.42 1.29 0.55 0.54 0.82 0.70 0.61

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The liquidity profile exhibits a period of significant volatility between early 2022 and late 2023, followed by a phase of gradual stabilization. A synchronized spike across all liquidity metrics occurred in October 2023, followed by a sharp contraction in December 2023, suggesting a substantial reallocation of short-term assets or a significant increase in current liabilities during that window.

Current Ratio
The current ratio fluctuated between 0.86 and 2.38. A peak of 2.38 was reached in October 2023, marking the highest point of short-term solvency in the analyzed period. This was immediately followed by a decline to 0.91 in December 2023. From 2024 through September 2026, the ratio demonstrates a steady recovery, trending upward from 1.00 to 1.42.
Quick Ratio
The quick ratio shows a similar trajectory, peaking at 1.78 in October 2023 before dropping to 0.50 in December 2023. The subsequent recovery has been more tempered than that of the current ratio, with values largely remaining below 1.00 for the majority of the 2024-2026 period, ending at 0.90 in September 2026. This divergence suggests that a larger portion of current assets is held in less liquid forms, such as inventory.
Cash Ratio
The cash ratio experienced the most pronounced volatility, reaching a high of 1.42 in October 2023 and falling to a low of 0.27 in December 2023. Throughout 2024 and 2025, the ratio remained relatively suppressed, fluctuating between 0.16 and 0.48. An upward trend emerged toward the end of the period, concluding at 0.45 in September 2026, indicating a gradual rebuilding of cash reserves relative to current liabilities.

Overall, the liquidity metrics indicate a transition from a high-liquidity position in late 2023 to a more lean operational structure. While the sharp decline at the end of 2023 created a temporary dip in solvency margins, the consistent improvement seen throughout 2025 and 2026 reflects a return toward a stable and sustainable liquidity baseline.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Current Ratio

Pfizer Inc., current ratio calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Current assets 45,009 41,358 42,822 42,898 46,924 43,703 45,861 50,358 43,223 37,825 42,415 43,333 74,012 73,347 50,078 51,259 70,403 67,466 54,420
Current liabilities 31,726 32,646 34,348 36,984 36,596 37,726 36,452 42,995 43,211 43,819 40,497 47,794 31,136 34,647 36,562 42,138 44,314 47,410 39,268
Liquidity Ratio
Current ratio1 1.42 1.27 1.25 1.16 1.28 1.16 1.26 1.17 1.00 0.86 1.05 0.91 2.38 2.12 1.37 1.22 1.59 1.42 1.39
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.87 0.81 0.80 0.67 0.72 0.74 0.76 0.66 0.65 0.81 0.94 0.87 0.96 0.89 0.96 0.96 0.93 0.84 0.82
Amgen Inc. 1.48 1.37 1.26 1.14 1.28 1.31 1.17 1.26 1.32 1.26 1.42 1.65 2.86 2.77 3.14 1.41 1.68 1.53 1.44
Bristol-Myers Squibb Co. 1.59 1.53 1.42 1.26 1.27 1.21 1.28 1.25 1.24 1.16 1.11 1.43 1.18 1.39 1.42 1.25 1.42 1.44 1.32
Danaher Corp. 1.63 1.65 1.87 1.87 1.52 1.62 1.43 1.40 1.37 1.43 1.85 1.68 2.26 2.08 1.89 1.89 1.78 1.75 1.68
Eli Lilly & Co. 1.39 1.35 1.50 1.58 1.55 1.28 1.37 1.15 1.27 1.11 1.35 0.94 1.05 1.13 1.30 1.05 1.13 1.10 1.27
Gilead Sciences Inc. 1.38 1.27 1.97 1.55 1.45 1.32 1.37 1.60 1.26 1.14 1.08 1.43 1.34 1.02 1.28 1.29 1.30 1.43 1.48
Johnson & Johnson 1.02 1.09 1.03 1.03 1.07 1.01 1.26 1.11 1.03 1.07 1.17 1.16 1.21 1.12 1.07 0.99 1.43 1.42 1.39
Merck & Co. Inc. 1.35 1.32 1.30 1.54 1.66 1.42 1.41 1.36 1.36 1.47 1.25 1.25 1.38 1.28 1.44 1.47 1.46 1.39 1.40
Regeneron Pharmaceuticals Inc. 3.35 3.34 3.57 4.13 4.06 4.60 4.93 4.73 5.28 5.44 5.27 5.69 5.18 5.45 5.45 5.06 5.36 5.12 4.76
Thermo Fisher Scientific Inc. 1.81 1.55 1.53 1.89 1.50 1.93 1.77 1.66 1.63 1.72 1.70 1.75 1.63 1.42 1.27 1.48 1.74 1.65 1.56
Vertex Pharmaceuticals Inc. 2.34 3.19 3.02 2.90 2.36 2.52 2.65 2.69 2.47 2.52 3.50 3.99 4.08 4.14 4.28 4.83 4.70 4.50 4.75

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= 45,009 ÷ 31,726 = 1.42

2 Click competitor name to see calculations.


The liquidity position exhibited significant volatility between April 2022 and September 2026, characterized by a period of substantial expansion followed by a sharp contraction and subsequent stabilization.

Current Ratio Trajectory
The current ratio began at 1.39 in April 2022, experiencing an initial rise to 1.59 by October 2022. A period of peak liquidity occurred between July and October 2023, where the ratio climbed sharply to reach a maximum of 2.38. However, this was followed by a precipitous decline to 0.91 by December 31, 2023, marking a shift where current liabilities exceeded current assets. The ratio remained under pressure through June 2024, hitting a low of 0.86, before recovering and stabilizing within a range of 1.16 to 1.42 through September 2026.
Current Asset Dynamics
Current assets showed high variance during the first two years of the period, peaking at 74,012 million US$ in October 2023. A significant reduction in liquid assets followed, reaching a minimum of 37,825 million US$ by June 30, 2024. From late 2024 through 2026, assets entered a more stable phase, fluctuating moderately between 41,358 million US$ and 50,358 million US$.
Current Liability Fluctuations
Current liabilities peaked in December 2023 at 47,794 million US$, coinciding with the sharpest drop in the current ratio. Prior to this, liabilities had decreased to a low of 31,136 million US$ in October 2023. From March 2024 onward, liabilities showed a gradual downward trend, declining from 40,497 million US$ to 31,726 million US$ by September 27, 2026, which contributed to the late-period improvement in the liquidity ratio.

The analysis indicates that while the company faced a temporary liquidity deficit in late 2023 and early 2024, it successfully restored its short-term solvency. The trend from September 2024 through September 2026 reflects a disciplined management of short-term obligations, resulting in a strengthened and more consistent current ratio.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Quick Ratio

Pfizer Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cash and cash equivalents 1,824 976 1,703 1,142 1,343 1,638 1,430 1,043 1,092 1,052 719 2,853 3,148 2,632 2,166 416 1,298 1,780 2,470
Short-term investments 12,448 10,723 11,372 12,454 13,641 11,611 15,887 19,434 8,860 6,048 11,209 9,837 41,033 42,153 17,806 22,316 34,825 31,524 21,427
Trade accounts receivable, net of allowance for doubtful accounts 14,192 12,490 12,585 11,874 14,260 12,078 11,845 11,463 14,451 11,393 10,989 11,177 11,086 10,231 12,305 10,952 16,076 15,155 13,225
Total quick assets 28,464 24,189 25,660 25,470 29,244 25,327 29,162 31,940 24,403 18,493 22,917 23,867 55,267 55,016 32,277 33,684 52,199 48,459 37,122
 
Current liabilities 31,726 32,646 34,348 36,984 36,596 37,726 36,452 42,995 43,211 43,819 40,497 47,794 31,136 34,647 36,562 42,138 44,314 47,410 39,268
Liquidity Ratio
Quick ratio1 0.90 0.74 0.75 0.69 0.80 0.67 0.80 0.74 0.56 0.42 0.57 0.50 1.78 1.59 0.88 0.80 1.18 1.02 0.95
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.56 0.49 0.52 0.41 0.47 0.48 0.48 0.42 0.43 0.59 0.72 0.63 0.71 0.63 0.66 0.69 0.69 0.57 0.52
Amgen Inc. 1.01 0.95 0.85 0.73 0.82 0.82 0.74 0.81 0.80 0.75 0.84 0.99 2.41 2.34 2.62 0.95 1.17 0.99 0.90
Bristol-Myers Squibb Co. 1.24 1.16 1.04 0.94 0.99 0.91 0.94 0.91 0.84 0.78 0.78 1.04 0.77 0.94 1.01 0.87 0.98 1.07 1.03
Danaher Corp. 1.08 1.03 1.28 1.25 0.84 0.96 0.83 0.83 0.84 0.85 1.34 1.18 1.76 1.52 1.34 1.30 1.19 1.13 1.08
Eli Lilly & Co. 0.64 0.68 0.72 0.78 0.73 0.53 0.57 0.58 0.62 0.60 0.67 0.52 0.58 0.63 0.79 0.62 0.70 0.66 0.77
Gilead Sciences Inc. 0.95 0.75 1.31 1.06 1.01 0.89 1.00 1.20 0.82 0.69 0.72 1.06 0.98 0.78 0.95 0.99 0.96 1.06 1.06
Johnson & Johnson 0.65 0.73 0.69 0.69 0.71 0.68 0.96 0.78 0.70 0.77 0.84 0.82 0.86 0.84 0.81 0.71 1.10 1.09 1.06
Merck & Co. Inc. 0.78 0.71 0.66 0.93 1.06 0.79 0.80 0.84 0.88 0.88 0.68 0.68 0.83 0.74 0.90 0.93 0.90 0.85 0.84
Regeneron Pharmaceuticals Inc. 2.72 2.63 2.84 3.28 3.19 3.57 3.90 3.86 4.34 4.43 4.40 4.82 4.31 4.53 4.54 4.16 4.37 4.20 3.95
Thermo Fisher Scientific Inc. 1.23 1.01 0.97 1.36 0.95 1.29 1.20 1.14 1.13 1.24 1.19 1.27 1.13 0.89 0.80 1.06 1.06 0.98 0.97
Vertex Pharmaceuticals Inc. 1.72 2.54 2.38 2.24 1.84 2.00 2.12 2.17 2.08 2.10 3.15 3.60 3.74 3.82 3.95 4.46 4.28 4.14 4.37

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 28,464 ÷ 31,726 = 0.90

2 Click competitor name to see calculations.


The liquidity position exhibited significant volatility between April 2022 and September 2026, characterized by a period of strong liquidity expansion followed by a sharp contraction and a subsequent gradual recovery.

Quick Ratio Performance
The quick ratio fluctuated from a starting point of 0.95 in April 2022 to a peak of 1.78 in October 2023, indicating a period of high short-term solvency. However, a precipitous decline followed, with the ratio falling to a low of 0.42 by June 2024. Since that trough, a steady recovery trend has been observed, with the ratio climbing back to 0.90 by September 2026.
Quick Asset Dynamics
Total quick assets showed substantial variance, reaching a maximum of 55.27 billion USD in October 2023. A significant reduction in these assets occurred throughout 2024, reaching a minimum of 18.49 billion USD in June 2024. In the final period analyzed, assets stabilized, trending upward to end at 28.46 billion USD in September 2026.
Current Liabilities Trend
Current liabilities peaked at 47.79 billion USD in December 2023, which coincided with a sharp drop in the quick ratio. Following this peak, a general downward trend in obligations is evident, with liabilities decreasing to 31.73 billion USD by September 2026. This reduction in short-term obligations contributed to the gradual improvement of the liquidity ratio in the latter half of the analyzed period.
Liquidity Correlation
The volatility in the quick ratio was primarily driven by the inverse relationship between the rapid depletion of quick assets and the spike in current liabilities observed between late 2023 and mid-2024. The subsequent recovery in the ratio was achieved through a combination of modest asset growth and a consistent reduction in current liabilities.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Cash Ratio

Pfizer Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cash and cash equivalents 1,824 976 1,703 1,142 1,343 1,638 1,430 1,043 1,092 1,052 719 2,853 3,148 2,632 2,166 416 1,298 1,780 2,470
Short-term investments 12,448 10,723 11,372 12,454 13,641 11,611 15,887 19,434 8,860 6,048 11,209 9,837 41,033 42,153 17,806 22,316 34,825 31,524 21,427
Total cash assets 14,272 11,699 13,075 13,596 14,984 13,249 17,317 20,477 9,952 7,100 11,928 12,690 44,181 44,785 19,972 22,732 36,123 33,304 23,897
 
Current liabilities 31,726 32,646 34,348 36,984 36,596 37,726 36,452 42,995 43,211 43,819 40,497 47,794 31,136 34,647 36,562 42,138 44,314 47,410 39,268
Liquidity Ratio
Cash ratio1 0.45 0.36 0.38 0.37 0.41 0.35 0.48 0.48 0.23 0.16 0.29 0.27 1.42 1.29 0.55 0.54 0.82 0.70 0.61
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.25 0.16 0.22 0.12 0.14 0.16 0.14 0.14 0.17 0.31 0.44 0.34 0.38 0.27 0.24 0.31 0.36 0.25 0.19
Amgen Inc. 0.57 0.55 0.48 0.36 0.43 0.39 0.38 0.52 0.44 0.43 0.49 0.60 2.05 2.00 2.22 0.59 0.80 0.57 0.51
Bristol-Myers Squibb Co. 0.67 0.59 0.55 0.46 0.59 0.49 0.49 0.46 0.36 0.29 0.37 0.55 0.33 0.43 0.49 0.42 0.48 0.63 0.66
Danaher Corp. 0.63 0.54 0.76 0.68 0.24 0.44 0.30 0.31 0.36 0.35 0.90 0.71 1.31 1.02 0.85 0.71 0.64 0.53 0.49
Eli Lilly & Co. 0.10 0.19 0.14 0.21 0.24 0.09 0.10 0.12 0.14 0.12 0.13 0.10 0.11 0.14 0.22 0.12 0.17 0.17 0.18
Gilead Sciences Inc. 0.54 0.29 0.81 0.65 0.60 0.47 0.64 0.83 0.43 0.26 0.36 0.64 0.57 0.48 0.56 0.57 0.54 0.61 0.62
Johnson & Johnson 0.31 0.38 0.38 0.37 0.36 0.35 0.68 0.49 0.39 0.47 0.54 0.50 0.53 0.53 0.54 0.42 0.75 0.73 0.70
Merck & Co. Inc. 0.34 0.26 0.21 0.51 0.64 0.33 0.37 0.48 0.49 0.44 0.22 0.28 0.38 0.27 0.45 0.54 0.49 0.44 0.40
Regeneron Pharmaceuticals Inc. 1.50 1.45 1.71 1.97 1.91 2.04 2.34 2.28 2.68 2.80 2.94 3.17 2.75 2.88 2.89 2.46 2.44 2.49 2.34
Thermo Fisher Scientific Inc. 0.43 0.27 0.22 0.67 0.24 0.50 0.45 0.42 0.46 0.60 0.52 0.58 0.43 0.22 0.22 0.50 0.26 0.17 0.23
Vertex Pharmaceuticals Inc. 1.26 1.99 1.87 1.71 1.40 1.54 1.64 1.72 1.64 1.63 2.68 3.16 3.31 3.35 3.44 3.93 3.74 3.62 3.78

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 14,272 ÷ 31,726 = 0.45

2 Click competitor name to see calculations.


The liquidity position over the analyzed period is characterized by extreme volatility, featuring a significant peak in late 2023 followed by a sharp contraction and a subsequent period of relative stabilization at lower levels.

Liquidity Expansion and Peak
From April 2022 through October 2023, a general upward trend in immediate liquidity is observed. Total cash assets increased from 23,897 million USD to a peak of 44,785 million USD in July 2023. This growth culminated in a peak cash ratio of 1.42 in October 2023, indicating that the entity held sufficient cash and cash equivalents to cover its current liabilities more than once over.
Rapid Liquidity Contraction
A severe decline in the cash ratio occurred between October 2023 and June 2024. In December 2023, total cash assets dropped precipitously to 12,690 million USD, coinciding with a spike in current liabilities to 47,794 million USD. This dual movement resulted in the cash ratio falling to 0.27, eventually reaching a period low of 0.16 by June 2024, the lowest point in the analyzed timeframe.
Stabilization and Recovery Phase
Beginning in late 2024, the liquidity profile entered a stabilization phase. The cash ratio recovered to 0.48 by December 2024. Throughout 2025 and into September 2026, the ratio fluctuated within a narrow range between 0.35 and 0.45. During this period, current liabilities trended downward from approximately 37,000 million USD to 31,726 million USD, while cash assets remained relatively steady between 11,000 million USD and 14,000 million USD.
Correlation Between Cash Assets and Liabilities
The volatility of the cash ratio was driven more by fluctuations in total cash assets than by changes in current liabilities. The most dramatic shifts in the ratio correspond directly with the rapid depletion of cash assets observed in late 2023 and the subsequent modest recovery in 2024.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?